Özge Karakök

Özge Karakök

Auto-generated profile, based on publicly available information

Özge Karakök

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Modern Rheumatology
Verified
Journal Article
Closed access
ÖKÖzge Karakök
Özge Karakök
SKSeda Kutluğ-Ağaçkıran
Seda Kutluğ-Ağaçkıran
RERabia Ergelen
Rabia Ergelen
TETülin Ergun
Tülin Ergun
HDHaner Direskeneli
Haner Direskeneli
FAFatma Alibaz-Oner
Fatma Alibaz-Oner
Objective: We aimed to follow patients classified as probable Behçet’s disease (BD) prospectively, conducting an inception cohort with patients diagnosed only within the last 6 months. Methods: We included 55 patients with probable BD. Fulfilment of classification criteria, new major organ involvement, and immunosuppressive (IS) usage were assessed during follow-up. Results: Initially, no patient fulfilled the International Study Group criteria. The median follow-up duration was 48 (21–77.5) months. Initially, 45 (81.8%) patients had major organ involvement. In 51 (92.7%) patients, bilateral common femoral vein wall thickness exceeded the 0.5 mm cut-off (Bilateral median common femoral vein wall thickness: 0.7 mm (0.70–0.80)). During follow-up, new major organ involvement was observed in 16 (29.1%) patients who needed step-up treatment with ISs. Six patients (10.9%) also developed new symptoms and subsequently fulfilled one or more diagnostic criteria. Two (3.6%) patients with pulmonary artery aneurysm had deceased due to massive haemoptysis. Conclusions: According to the 48-month follow-up results of the probable BD inception cohort, the majority of BD patients who had limited clinical findings started with major organ involvement. Only six (10.9%) patients developed new manifestations during follow-up, and these patients subsequently met the International Study Group and/or International Criteria for Behçet’s Disease criteria. Additionally, 16 patients (29.1%) experienced new or relapsed major organ involvement. Key messages:

15 August 2025 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
ÖKÖzge Karakök
Özge Karakök
TBTuğçe Bozkurt
Tuğçe Bozkurt
TETulin Ergun
Tulin Ergun
HDHaner Direskeneli
Haner Direskeneli
FAFatma Alibaz-Oner
Fatma Alibaz-Oner

16 June 2026 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
ÖKÖzge Karakök
Özge Karakök
DKDuygu Keri̇m
Duygu Keri̇m
ŞÇŞeri̇fE Çoşkun-Sağirkaya
Şeri̇fE Çoşkun-Sağirkaya
GAGamze Akkuzu
Gamze Akkuzu
BUBurcu Ceren Uludoğan
Burcu Ceren Uludoğan
FAFatma Alibaz-Oner
Fatma Alibaz-Oner
Background/aim: In Behçet’s disease (BD), arterial involvement represents a significant clinical challenge associated with serious complications. The present study evaluates the characteristic features, affected vessels, lesion types, treatments, and outcomes in BD patients with nonpulmonary arterial involvement. Materials and methods: Included in this retrospective study were 65 BD patients whose interventions and clinical courses were accessed from medical records. The treatments administered included immunosuppressive (IS) therapies and surgical/endovascular procedures. Fisher’s exact and t-test/Mann–Whitney U test were used for statistical analysis. Results: Fifty-nine of the patients (90.8%) were male. The median (Q1–Q3) follow-up was 4 (2–12.8) years. The most commonly affected vessels were the aorta (n = 21, 32.3%) and the femoral artery (n = 19, 29.2%). Aneurysm (n = 50, 63.2%) and thrombosis (n = 18, 22.7%) were the predominant lesions; 14 (21.5%) patients experienced arterial involvement while receiving IS therapy; and 11 (16.9%) had cardiac involvement. Cyclophosphamide and azathioprine were the most commonly used IS agents. Among the 39 (60%) patients who underwent surgical and/or interventional procedures, 32 (82%) had successful outcomes. A second arterial event was experienced by 15.3% of the sample during follow-up, and a third by 3%. Active disease was noted in nine (13.8%) patients at the time of their last visit, and of the six (9.2%) that died, most had both arterial and cardiac involvement. Conclusion: Arterial involvement in BD mostly presents with aneurysms, especially in men. Surgical interventions in addition to IS therapies are required in approximately 50% of cases. As can be understood from the 15.3% relapse rate in the present study, arterial events are not uncommon, underlining the need for long-term monitoring and sustained IS treatment. Of the 9.2% of cases who died, most had both arterial and cardiac involvement.

7 April 2026 in Internal and Emergency Medicine
Verified
Journal Article
Open access
TYTuba Demirci Yildirim
Tuba Demirci Yildirim
EEEsra Erpek
Esra Erpek
BUBahar Özdemir Ulusoy
Bahar Özdemir Ulusoy
GUGullu Sandal Uzun
Gullu Sandal Uzun
AYAyten Yazici
Ayten Yazici
FOFatos Onen
Fatos Onen
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.